Compare Ginkgo Bioworks Holdings Inc (DNA) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Banco Santander SA — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Banco Santander SA trades at $13.6 (market cap $195.40B). The key difference: Banco Santander SA is far larger — about 330.9× Ginkgo Bioworks Holdings Inc's market cap, and Banco Santander SA pays a 2.04% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | SAN | |
|---|---|---|
Market Cap | $590.53M | $195.40B |
Sector | Health | Financials |
52-Week High | $16.14 | $14.37 |
52-Week Low | $5.48 | $8.31 |
Enterprise Value | $627.78M | — |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Banco Santander (SAN) trades at $13.66, down 1.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 EPS of $0.4144, beating expectations, and maintains a strong net income margin of 26.72%. Recent developments include the acquisition of TSB and AI-driven efficiency initiatives targeting over $1.15 billion in business value. The stock shows a P/E of 13.57 and P/B of 1.62, indicating reasonable valuation relative to peers.
The outlook for SAN is positive, supported by record profitability, strategic acquisitions, and cost-saving measures. However, risks include declining cash flows, regulatory scrutiny in Spain, and macroeconomic pressures on loan growth. Analyst consensus is bullish with 64% buy ratings, but investors should monitor execution on efficiency targets and integration of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
